What key pharmacokinetic properties did MIRA's SKNY-1 demonstrate in preclinical studies?

SKNY-1 demonstrated favorable oral bioavailability, reproducible systemic exposure, robust brain penetration, and substantial liver exposure in preclinical studies.

How does SKNY-1’s profile support its clinical development for obesity and addiction?

SKNY-1’s optimized formulation supports once-daily dosing and combines unique pharmacology to address both obesity and addiction while potentially avoiding neuropsychiatric side effects associated with earlier CB1-targeting therapies.

MIRA's obesity-and-addiction drug shows brain and liver exposure

Jul 6, 2026

MIRA Pharmaceuticals announced positive preclinical results for SKNY-1, an oral drug for obesity and addiction, showing robust brain and liver exposure that supports once-daily dosing.

Stock Titan

2026-07-06

MIRA's obesity-and-addiction drug shows brain and liver exposure

2026-08-22

Bank of New York Mellon Purchases 2.6 Million Shares in PPG Industries

2026-11-05

Mirae Asset Initiates New Position in PPG Industries with 77,319 Shares

MIRA's obesity-and-addiction drug shows brain and liver exposure

FAQ